These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 16328054

  • 21. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM.
    Cancer Res; 2000 Sep 15; 60(18):5165-70. PubMed ID: 11016644
    [Abstract] [Full Text] [Related]

  • 22. Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells.
    Lee KW, Kim JH, Park JH, Kim HP, Song SH, Kim SG, Kim TY, Jong HS, Jung KH, Im SA, Kim TY, Kim NK, Bang YJ.
    Anticancer Res; 2006 Sep 15; 26(5A):3429-38. PubMed ID: 17094463
    [Abstract] [Full Text] [Related]

  • 23. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines.
    Shen J, Huang C, Jiang L, Gao F, Wang Z, Zhang Y, Bai J, Zhou H, Chen Q.
    Biochem Pharmacol; 2007 Jun 15; 73(12):1901-9. PubMed ID: 17445779
    [Abstract] [Full Text] [Related]

  • 24. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
    Ogawa T, Hayashi T, Tokunou M, Nakachi K, Trosko JE, Chang CC, Yorioka N.
    Cancer Res; 2005 Nov 01; 65(21):9771-8. PubMed ID: 16266998
    [Abstract] [Full Text] [Related]

  • 25. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
    Kelly WK, Marks PA.
    Nat Clin Pract Oncol; 2005 Mar 01; 2(3):150-7. PubMed ID: 16264908
    [Abstract] [Full Text] [Related]

  • 26. Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids.
    Lobjois V, Frongia C, Jozan S, Truchet I, Valette A.
    Eur J Cancer; 2009 Sep 01; 45(13):2402-11. PubMed ID: 19553104
    [Abstract] [Full Text] [Related]

  • 27. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
    Park KC, Kim SW, Park JH, Song EH, Yang JW, Chung HJ, Jung HJ, Suh JS, Kwon HJ, Choi SH.
    Cancer Sci; 2011 Feb 01; 102(2):343-50. PubMed ID: 21159061
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells.
    Ahn MY, Jung JH, Na YJ, Kim HS.
    Gynecol Oncol; 2008 Jan 01; 108(1):27-33. PubMed ID: 17920664
    [Abstract] [Full Text] [Related]

  • 34. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY, Chang JW, Chou WC, Liaw CC, Wang HM, Huang JS, Wang CH, Yeh KY.
    Lung Cancer; 2008 Feb 01; 59(2):180-91. PubMed ID: 17900752
    [Abstract] [Full Text] [Related]

  • 35. Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid.
    Tong A, Zhang H, Li Z, Gou L, Wang Z, Wei H, Tang M, Liang S, Chen L, Huang C, Wei Y.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(5):791-802. PubMed ID: 17593366
    [Abstract] [Full Text] [Related]

  • 36. Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents.
    Dong G, Wang L, Wang CY, Yang T, Kumar MV, Dong Z.
    J Pharmacol Exp Ther; 2008 Jun 01; 325(3):978-84. PubMed ID: 18310471
    [Abstract] [Full Text] [Related]

  • 37. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N, Rathos M, Chaudhari U, Sivaramakrishnan H, Joshi K.
    Lung Cancer; 2013 Nov 01; 82(2):214-21. PubMed ID: 24051085
    [Abstract] [Full Text] [Related]

  • 38. Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
    Koshimune R, Aoe M, Toyooka S, Hara F, Ouchida M, Tokumo M, Sano Y, Date H, Shimizu N.
    BMC Cancer; 2007 Jan 12; 7():8. PubMed ID: 17222343
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.